With the recent approval of silicone gel-filled breast implants for breast augmentation and breast reconstruction, physicians and patients can be assured of the safety of silicone. This confirmation is based on extensive preclinical testing, four years of data on 715 women from Allergan's Core Clinical Study and a European study that evaluated implant rupture prevalence rates beyond 10 years. In addition, countless published, peer-reviewed studies and research support the safety of silicone gel-filled breast implants.
A study by the US Government looks at silicone gel-filled breast implants and confirms findings. In 1997, the Department of Health and Human Services began one of the most extensive research studies in medical history by appointing the Institute of Medicine of the National Academy of Science (IOM) to examine potential complications during or after surgery. The IOM consisted of a 13-member volunteer committee, including six women. The committee was composed of members of the medical, scientific and educational communities with experience in radiology, women's health, neurology, oncology, silicone chemistry, rheumatology, immunology, epidemiology, internal medicine and plastic surgery. No IOM members had on-going relationships or conflicts of interest related to any implant lawsuits.
The result: After reviewing years of evidence and research concerning silicone gel-filled breast implants, the IOM found that "Evidence suggests diseases or conditions such as connective tissue diseases, cancer, neurological diseases or other systemic complaints or conditions are no more common in women with breast implants than in women without implants."
Furthermore, a review of research and medical studies shows:
- Extensive studies, including a report by the Institute of Medicine, conclude that breast cancer is no more common in women with implants than in those without implants
- The American Academy of Pediatrics concluded in September 2001 "The Committee on Drugs does not feel that the evidence currently justifies classifying silicone implants as a contraindication to breastfeeding."
- Epidemiological investigations have not found any increased risk of adverse health outcomes… in children born to women with breast
For more information log onto: http://www.thepatientsadvantage.com.
A study by the US Government looks at silicone gel-filled breast implants and confirms findings. In 1997, the Department of Health and Human Services began one of the most extensive research studies in medical history by appointing the Institute of Medicine of the National Academy of Science (IOM) to examine potential complications during or after surgery. The IOM consisted of a 13-member volunteer committee, including six women. The committee was composed of members of the medical, scientific and educational communities with experience in radiology, women's health, neurology, oncology, silicone chemistry, rheumatology, immunology, epidemiology, internal medicine and plastic surgery. No IOM members had on-going relationships or conflicts of interest related to any implant lawsuits.
The result: After reviewing years of evidence and research concerning silicone gel-filled breast implants, the IOM found that "Evidence suggests diseases or conditions such as connective tissue diseases, cancer, neurological diseases or other systemic complaints or conditions are no more common in women with breast implants than in women without implants."
Furthermore, a review of research and medical studies shows:
- Extensive studies, including a report by the Institute of Medicine, conclude that breast cancer is no more common in women with implants than in those without implants
- The American Academy of Pediatrics concluded in September 2001 "The Committee on Drugs does not feel that the evidence currently justifies classifying silicone implants as a contraindication to breastfeeding."
- Epidemiological investigations have not found any increased risk of adverse health outcomes… in children born to women with breast
For more information log onto: http://www.thepatientsadvantage.com.
SHARE
